Cell-Penetrating Peptides: How They Enter Cells

Penetratin

< 30 amino acids

Cell-penetrating peptides are typically fewer than 30 amino acids long, yet they can ferry cargo molecules up to 100 times their own mass across the cell membrane.

Derakhshankhah and Hosseinzadeh, Biomedicine and Pharmacotherapy, 2018

Derakhshankhah and Hosseinzadeh, Biomedicine and Pharmacotherapy, 2018

View as image

The cell membrane is biology's security gate. It keeps the contents of a cell in and foreign molecules out, which is exactly what makes drug delivery so difficult. Most therapeutic molecules, particularly large ones like proteins, antibodies, and nucleic acids, cannot cross this barrier on their own. Cell-penetrating peptides (CPPs) are short amino acid sequences, typically fewer than 30 residues, that have the unusual ability to traverse cell membranes and carry cargo along with them. Since the discovery of the TAT peptide from HIV-1 and penetratin from the Drosophila Antennapedia protein in the late 1980s, CPPs have become one of the most studied tools in drug delivery research.

A 2018 review by Derakhshankhah and Hosseinzadeh cataloged the known CPP families and their applications, noting that CPPs can deliver cargoes ranging from small molecule drugs to nanoparticles, with high efficiency and generally low toxicity.^[1] Despite three decades of research, no CPP-based drug has yet received FDA approval, though multiple candidates are in clinical trials. Understanding how CPPs actually enter cells, and the challenges that remain, is essential context for evaluating their therapeutic potential.

What Makes a Peptide "Cell-Penetrating"?

CPPs share several features that enable membrane crossing, but there is no single structural template. They are classified into three broad categories based on their physicochemical properties.^[1]

Cationic CPPs carry a high positive charge, typically from arginine and lysine residues. The TAT peptide (GRKKRRQRRRPPQ) is the prototype. Polyarginine sequences as short as eight residues (R8) can cross membranes effectively. The positive charge is critical: it drives electrostatic interaction with the negatively charged phospholipid headgroups and glycosaminoglycans on the cell surface.^[4]

Amphipathic CPPs contain both hydrophobic and hydrophilic regions, often arranged in an alpha-helical structure where one face is charged and the other is nonpolar. Penetratin and the model amphipathic peptide (MAP) fall into this category. Their membrane interaction involves both electrostatic binding and hydrophobic insertion.

Hydrophobic CPPs are dominated by nonpolar residues and rely on direct insertion into the lipid bilayer. They are less common and less well studied than cationic and amphipathic variants.

Arginine residues play a disproportionate role in CPP activity. Liu et al. reviewed the internalization mechanisms of arginine-rich CPPs across multiple species in 2022, finding that the guanidinium group of arginine forms bidentate hydrogen bonds with phosphate and sulfate groups on membrane lipids and proteoglycans, creating a unique mode of membrane interaction that lysine (with its single amino group) cannot replicate.^[4]

How CPPs Cross the Membrane: Two Routes

The mechanism by which CPPs enter cells has been debated since the field's inception. The current consensus is that two pathways operate, with their relative contributions depending on CPP concentration, cargo size, cell type, and membrane composition.^[7]

Direct Translocation

At high peptide concentrations, CPPs can cross the membrane without energy input through direct translocation. Three models describe this process:

The barrel-stave model proposes that peptides insert perpendicularly into the bilayer and assemble into a transmembrane pore through which cargo passes. The carpet model describes peptides accumulating on the membrane surface until they reach a threshold concentration that disrupts the bilayer, creating transient openings. The inverted micelle model, most relevant to penetratin, proposes that the peptide induces local invagination of both leaflets of the bilayer, forming a small lipid vesicle that encapsulates the peptide and transports it to the cytoplasmic side.^[1]

Reid et al. used molecular dynamics simulations in 2019 to examine these models at atomic resolution, finding that the specific mechanism depends heavily on membrane composition and that no single model explains all CPP-membrane interactions.^[7]

Endocytosis

At the lower concentrations relevant to therapeutic applications, endocytosis is the dominant entry pathway. CPPs trigger their own uptake through several endocytic routes: macropinocytosis (bulk fluid uptake), clathrin-mediated endocytosis, caveolae-mediated endocytosis, and clathrin/caveolae-independent pathways.^[4]

Macropinocytosis appears to be particularly important for cationic CPPs. The peptide's positive charge triggers clustering of cell surface proteoglycans, which activates signaling cascades that stimulate actin-dependent membrane ruffling and bulk uptake of extracellular fluid containing the CPP.

The endocytic pathway creates a fundamental problem: the CPP and its cargo end up trapped inside endosomes, acidic vesicles destined for lysosomal degradation. How CPPs escape these endosomal traps is the single biggest obstacle to effective CPP-mediated drug delivery.

The Endosomal Escape Problem

When CPPs enter cells via endocytosis, they are initially enclosed in early endosomes. As these vesicles mature and acidify (pH drops from 7.4 to approximately 5.0), their contents are typically routed to lysosomes for degradation. For a CPP-drug conjugate to work, the cargo must escape the endosome and reach the cytoplasm before this happens.

Sahni et al. published a study in 2020 that challenged the prevailing assumption about how CPPs escape endosomes. Using live-cell imaging with fluorescent reporters, they showed that CPPs do not punch holes in endosomal membranes (the "pore model"). Instead, CPPs induce endosomal vesicle budding and collapse, releasing their contents in a burst when the vesicle loses structural integrity.^[3] This mechanism has implications for CPP design: rather than engineering peptides that form stable pores, the field may need to focus on peptides that destabilize vesicle structure at acidic pH.

Kondow-McConaghy et al. examined how CPP endosomal escape activity affects the broader endocytic pathway, finding that efficient escape can redirect trafficking from degradative to non-degradative routes, potentially improving the therapeutic window of CPP-drug conjugates.^[6]

The efficiency of endosomal escape remains poor. Estimates suggest that only 1 to 5% of endocytosed CPP molecules reach the cytoplasm. This means that even though CPPs are efficient at entering cells, the vast majority of internalized drug is destroyed before reaching its target. Solving this problem is the field's highest priority.

Engineering Better CPPs: Cyclic and Stapled Designs

The limitations of linear CPPs have driven intensive engineering efforts. Two approaches stand out for their impact on endosomal escape and metabolic stability.

Cyclic CPPs

Buyanova and Bhatt reported in 2022 the discovery of a cyclic cell-penetrating peptide with dramatically improved endosomal escape and cytosolic delivery efficiency compared to linear CPPs.^[5] The cyclic structure constrains the peptide into a conformation that enhances membrane interaction while simultaneously increasing resistance to proteolytic degradation. In direct comparison, the cyclic CPP achieved cytosolic delivery efficiency four to six times greater than linear TAT, the benchmark peptide in the field.

Cyclization also addresses a practical limitation: linear CPPs are rapidly degraded by serum proteases, limiting their in vivo half-life. The constrained structure of cyclic CPPs makes them harder for proteases to cleave, extending circulation time and increasing the fraction of peptide that reaches target cells intact.

Stapled Peptides

Stapling introduces a covalent bond between amino acid side chains, locking the peptide into an alpha-helical conformation. This improves membrane affinity (alpha-helices insert more readily into lipid bilayers), protease resistance, and in some cases, target binding affinity. Several stapled CPP designs have shown improved cellular uptake in preclinical studies.

Drug Delivery Applications

CPPs have been explored for delivering virtually every class of therapeutic molecule. The most advanced applications span oncology, genetic disease, and ophthalmology.

Cancer Therapeutics

Bottens and Bhatt reviewed the use of CPPs in cancer diagnosis and treatment in 2022, documenting applications in delivering chemotherapy drugs, tumor-targeting imaging agents, and immunotherapy cargo directly into cancer cells.^[8] ATX-101, a CPP conjugate that induces caspase-dependent apoptosis in cancer cells and sensitizes them to conventional chemotherapy, has advanced to clinical trials for solid tumors and hematological malignancies.

A key advantage of CPPs in oncology is their potential for tumor selectivity. By conjugating CPPs to tumor-homing sequences or designing activatable CPPs that are cleaved only by tumor-associated proteases, researchers can concentrate drug delivery at the tumor site while reducing systemic toxicity.^[8]

Genetic Diseases

Reissmann and Bhatt highlighted the clinical progress of PGN-EDO51, a CPP fused to an exon-skipping oligonucleotide for the treatment of Duchenne muscular dystrophy (DMD).^[2] The CPP enables the oligonucleotide to penetrate muscle cell membranes and reach the nucleus, where it redirects splicing of the dystrophin gene to produce a shortened but functional protein. This approach addresses the fundamental delivery barrier that has limited antisense oligonucleotide therapies for muscular dystrophies.

Ophthalmology and Topical Delivery

The eye presents unique delivery challenges because multiple biological barriers protect intraocular tissues. CPPs have been tested as carriers for anti-inflammatory drugs, anti-VEGF agents, and gene therapy vectors for retinal diseases. The corneal epithelium, in particular, is amenable to CPP-mediated delivery because of its accessible surface and the local application route, which avoids systemic dilution.^[1]

What Limits CPPs From Clinical Use?

Despite three decades of research, no CPP-based drug has received FDA approval. Several barriers persist:

Endosomal entrapment remains the primary bottleneck. Even with improved cyclic designs achieving four to six-fold increases in cytosolic delivery, the absolute efficiency of endosomal escape is still low compared to what many therapeutic applications require.^[5]

Lack of cell-type specificity is a fundamental issue. Most CPPs enter all cell types indiscriminately, which can cause off-target effects and dilute the drug across non-target tissues. Activatable and targeted CPP designs address this partially but add complexity and cost.

Proteolytic instability in serum limits the in vivo pharmacokinetics of linear CPPs. Cyclic and stapled designs mitigate this, but at the cost of more complex synthesis.

Immunogenicity concerns exist for peptide-based therapeutics generally, though CPPs' small size reduces this risk compared to larger protein therapeutics.

Scalability and cost of peptide synthesis remain barriers for CPP-drug conjugates that require GMP-grade manufacturing at scale. Solid-phase peptide synthesis is well-established but expensive relative to small molecule drug manufacturing.

The Bottom Line

Cell-penetrating peptides are short sequences that cross cell membranes through direct translocation or endocytosis, enabling intracellular delivery of drugs, proteins, and nucleic acids. The field has progressed from the discovery of TAT and penetratin in 1988 to engineered cyclic CPPs with four to six-fold improved cytosolic delivery. Endosomal escape remains the primary limitation, with only 1 to 5% of internalized CPP reaching the cytoplasm. Multiple clinical candidates are advancing, including ATX-101 for cancer and PGN-EDO51 for Duchenne muscular dystrophy, but FDA approval has not yet been achieved.

Frequently Asked Questions

What are cell-penetrating peptides?

Cell-penetrating peptides (CPPs) are short amino acid sequences, typically fewer than 30 residues, that can cross cell membranes and carry cargo molecules into cells. They were first discovered in 1988 when researchers observed that the TAT protein from HIV-1 could enter cells spontaneously. CPPs are classified into three types based on their properties: cationic (positively charged, like TAT), amphipathic (with both hydrophobic and hydrophilic faces, like penetratin), and hydrophobic.

How do cell-penetrating peptides enter cells?

CPPs enter cells through two main routes. Direct translocation occurs at high concentrations, where peptides physically cross the lipid bilayer through pore formation, membrane carpet disruption, or inverted micelle formation. Endocytosis, the dominant pathway at therapeutic concentrations, involves the cell actively engulfing the peptide into vesicles called endosomes. A 2022 review by Liu et al. found that arginine-rich CPPs interact with membrane phospholipids through unique bidentate hydrogen bonds that facilitate both pathways.

What is the endosomal escape problem in drug delivery?

When CPPs enter cells via endocytosis, they become trapped in endosomes, acidic vesicles that normally route their contents to lysosomes for destruction. Only an estimated 1 to 5% of internalized CPP molecules escape to the cytoplasm. Sahni et al. showed in 2020 that CPPs escape by inducing vesicle budding and collapse rather than forming pores. Solving this inefficiency is the field's top priority because it limits how much drug actually reaches its intracellular target.

Are cell-penetrating peptides used in medicine?

CPPs are in clinical development but none have received FDA approval yet. The most advanced candidates include ATX-101 (a CPP conjugate for cancer that sensitizes tumor cells to chemotherapy) and PGN-EDO51 (a CPP-oligonucleotide fusion for Duchenne muscular dystrophy). CPPs are also being tested for ophthalmic drug delivery and as carriers for gene therapy vectors. Reissmann and Bhatt reviewed the clinical pipeline in 2021 and identified multiple candidates across oncology, genetic disease, and inflammation.

What is the difference between TAT peptide and penetratin?

TAT (GRKKRRQRRRPPQ) is a 13-residue cationic peptide derived from the HIV-1 transactivator protein, discovered in 1988. Penetratin (RQIKIWFQNRRMKWKK) is a 16-residue amphipathic peptide derived from the Drosophila Antennapedia homeodomain protein. Both cross cell membranes, but they use different mechanisms: TAT relies primarily on charge-mediated interactions with cell surface proteoglycans, while penetratin also uses hydrophobic insertion into the lipid bilayer through its tryptophan residues.

Can cell-penetrating peptides be made more effective?

Yes. Cyclic CPPs constrain the peptide into conformations that enhance membrane interaction and resist protease degradation. Buyanova and Bhatt reported in 2022 that a cyclic CPP achieved four to six times greater cytosolic delivery than linear TAT. Stapled peptides, which lock alpha-helical conformations with covalent crosslinks, also show improved uptake. Activatable CPPs that are triggered only by tumor-associated enzymes are being designed to improve cell-type specificity, addressing the lack of targeting that limits current CPP therapeutics.